FindTrial
Sign In

Comparative study on triamcinolone and bevacizumab efficacy in macular edema treatment and in retinic or chorioretinic neovessels treatment - ND

Comparative study on triamcinolone and bevacizumab efficacy in macular edema treatment and in retinic or chorioretinic neovessels treatment - ND

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-003032-37-IT
Enrollment
Unknown
Registered
2007-07-27
Start date
2007-05-30
Completion date
Unknown
Last updated
2012-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

macular edema MedDRA version: 9.1 Level: LLT Classification code 10025415 Term: Macular oedema

Interventions

Trade Name: AVASTIN*INFUS 1FL 100MG Pharmaceutical Form: Concentrate for solution for infusion INN or Proposed INN: Bevacizumab Concentration unit: mg milligram(s) Concentration type: equal Concentrat

Sponsors

OSPEDALE POLICLINICO S. MATTEO
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: macular edema Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: recent IMA (six months), severe hypertension not therapy-controlled

Design outcomes

Primary

MeasureTime frame
Main Objective: to evaluate triamcinolone and bevacizumab efficacy in macular edema treatment and side effects frequency;Secondary Objective: Secondary objectives are visual acuity, functional results and drug sistemic level.;Primary end point(s): thickness of the fybre—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026